Unbiased screening of large randomized chemical libraries in vivo is a powerful tool to find 17 new drugs and targets. However, forward chemical screens in zebrafish can be time consuming 18 and usually >99% of test compounds have no significant effect on the desired phenotype. Here, 19 we sought to find bioactive drugs more efficiently and to comply with the 3R principles of 20 replacement, reduction and refinement of animals in research. We investigated if pooling of 21 drugs to simultaneously test 8-10 compounds in zebrafish larvae can increase the screening 22 efficiency of an established assay that identifies drugs inhibiting developmental angiogenesis 23 in the eye. In a phenotype-based screen, we tested 1760 small molecule compounds from the 24 ChemBridge DIVERSet TM chemical library for their ability to inhibit the formation of distinct 25 primary hyaloid vessels in the eye. Applying orthogonal pooling of the chemical library, we 26 treated zebrafish embryos from 3 to 5 days post fertilization with pools of 8 or 10 compounds 27 at 10 µM each. This reduced the number of tests from 1760 to 396. In 63% of cases, treatment 28 showed sub-threshold effects of <40% reduction of primary hyaloid vessels. From 18 pool hits, 29 we identified 8 compounds that reduce hyaloid vessels in the larval zebrafish eye by at least 30 40%. Compound 4-[4-(1H-benzimidazol-2-yl)phenoxy]aniline ranked as the most promising 31 candidate with reproducible and dose-dependent effects. To our knowledge, this is the first 32 report of a self-deconvoluting matrix strategy applied to drug screening in zebrafish. We 33 conclude that the orthogonal drug pooling strategy is a cost-effective, time-saving and unbiased 34 approach to discover novel inhibitors of developmental angiogenesis in the eye. Ultimately, this 35 approach may identify new drugs or targets to mitigate disease caused by pathological 36 angiogenesis in the eye e.g. diabetic retinopathy or age-related macular degeneration wherein 37 blood vessel growth and leaky vessels lead to vision impairment or clinical blindness. 38 39 Keywords 40 41 Zebrafish, angiogenesis, eye vascular system, library screening, drug pooling, orthogonal 42 pooling strategy, self-deconvoluting matrix, 3R 43 44 Number of figures: 4 45 Number of words: 3698 46 47 48
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Drug treatments & Quantification
To determine the effect of test drugs on hyaloid vessel (HV) formation, 5 embryos were treated 139 at 2 days post fertilization (dpf) with single or pooled compounds at a starting concentration of 140 10 µM in a volume of 400 µL embryo medium ( Fig. 1A) (Alvarez et al., 2007; Hartsock et al., 141 2014). At 5 dpf, embryos were fixed with 4% PFA and lenses dissected from the eye to count 142 connected primary hyaloid vessels (Fig. 1C) (Alvarez et al., 2007) . To assess inhibition of 143 angiogenesis in the intersegmental vessel (ISV), embryos were treated from 6 to 72 hours post 144 fertilization (hpf). At 1.5 dpf, the ISVs that sprout from the dorsal aorta and elongated dorsally 145 have reached the most dorsal region of the trunk and formed a T shape. Once these vessels 146 connect they form a pair of dorsal longitudinal anastomotic vessels (DLAV) (Isogai et al., 147 2001). For quantification, all ISVs that reached the most dorsal position and were connected to 148 the DLAV were manually counted as 1. Absent vessels or sprouts without connection to the 149 or more dead larvae, the combination of drugs was considered "toxic". Unless all compounds 151 of a toxic combination were represented in other non-toxic pools, they were tested again 152 individually. 1% DMSO was used for negative vehicle control in pools and 0.1% DMSO as 153 vehicle control for individual treatments. 10 µM sunitinib (Sigma Aldrich #PZ0012) was used 154 as positive control (Faivre et al., 2007; Hao and Sadek, 2016) . The number of blood vessels 155 was determined using an Olympus stereo microscope (SZX10) and representative pictures 156 taken using Olympus DP71 camera and CellSens Standard software (Fig. 1C) . 157 158 Statistical Analysis 159 We wish to assess whether the means of two groups are statistically different from each other.
160
An independent sample t-test will evaluate if the data supports this claim but requires that the we reject the null hypothesis and conclude there is evidence of a significant difference between 170 the groups (* p-value <0.05, ** p-value <0.01 and *** p-value <0.001).
172 173
Results
175
Orthogonal Drug Pooling. 176 We decided on an orthogonal pooling strategy to evaluate both the feasibility and benefits 177 of drug pooling for identification of library chemicals which attenuate hyaloid vessel 178 development ( Fig. 1) . Our pooling strategy combined 10 drugs of each plate row (e.g. pool H) 179 and 8 drugs from each plate column (e.g. pool 5) into single pools ( Fig. 1B) with a final 180 concentration of 1% DMSO. This ensured that every compound was present in at least two 181 pools (e.g. H5 in pool H and pool 5) making it easier to distinguish true positives. As a 182 phenotype-based readout for anti-angiogenic activity, we counted the number of primary 183 hyaloid vessels in lenses dissected from 5 dpf eyes of Tg(fli1a:eGFP) embryos, following 3 184 days of drug treatment (Fig. 1C) . Sunitinib, a potent multi-tyrosine kinase inhibitor with known 185 anti-angiogenic properties at 10 µM was used as positive control. This method allows testing 186 of 80 compounds from one 96-well plate in 18 pools or the library of 1760 compounds (22 187 plates) to be tested in 396 pools ( Fig. 1D) . 188 189 Proof of Principle. 190 We first determined if the final pool concentration of 1% DMSO may non-specifically 191 generate an anti-angiogenic phenotype. In a dose-response analysis (ranging from 0.1 -3%) 192 DMSO, concentrations up to 2% DMSO had no effect on primary HV (PHV) formation (Fig. 193 2A). To implement and validate the adopted method, we first pooled 10 compounds of row D 194 and 8 compounds of column 4 from randomly chosen Diverset® plate 30331 ( Fig. 2B) . Pool 4 195 (3.0 +/-1.0 PHV) was indistinguishable from the vehicle controls (3.5 +/-0.6 PHV) ( Fig. 2B) . 196 Pool D induced a slight (2.6 +/-0.5 PHV) but significant (p<0.05) reduction by 25% in hyaloid 197 vessel number (Fig. 2B) . None of the ten constituent compounds (D2-D11) from pool D exerted 198 a significant anti-angiogenic effect on their own, however, D3 by itself reduced hyaloid vessel 199 (2.8+/-0.5 PHV OR 21% reduction) similar to pool D (Fig. 2B) . In contrast, when compound 200 D4 was replaced with 10 µM sunitinib in pool D or pool 4, robust antiangiogenic activity (0.2 +/-0.4 PHV, 94% reduction) was observed, equivalent to treating with 10 µM sunitinib alone 202 (0.3 +/-0.5 PHV, 91% reduction). We conclude that active anti-angiogenic compounds can be 203 detected in our drug pooling screen.
204
To scale-up the proof-of-concept screen, we tested all 80 compounds of randomly chosen 205 Diverset® plate 30251 in 18 pools ( Fig. 2C) . Compound H4 was replaced with 10 µM sunitinib 206 as a positive control. Reassuringly, pools H and 4, which contain 10 µM sunitinib, were true 207 positives resulting in 0.2 +/-0.4 and 0.4 +/-0.5 primary hyaloid vessels reflecting a 93% and 208 87% reduction respectively. There was a clear efficacy difference between these pools and the 209 non-spiked, inactive pools ( Fig. 2C) . 210 To address the concern that pooling compounds might mask active compounds, we 211 performed a dose-response curve for sunitinib to determine if the concentration at which 212 sunitinib no longer produced significant anti-angiogenic activity was different when 213 administered alone compared to in D pools from Diverset® plate 30331 ( Fig. 2D) . Larvae 214 treated with pool D alone were indistinguishable (2.8 +/-0.4 PHV, p>0.6) from 1% DMSO 215 vehicle controls. In general, the activity of sunitinib was equivalent in pools or alone, producing 216 robust, significant anti-angiogenic activity at 5 and 10 µM concentrations ( Fig. 2D) . At 2.5 µM, 217 sunitinib showed a significant reduction (p<0.05) in hyaloid vessel number in the pool and not 218 with sunitinib alone (p>0.1), and the fold reduction was significantly different (0.6 +/-0.9 and 219 2.2 +/-0.8 PHV). This was also reflected in embryo morphology with oedema present when 220 treated with 1 µM sunitinib in pool D but not with 1 µM sunitinib alone and more severe oedema 221 forming at 2.5 µM sunitinib in pool D than with 2.5 µM sunitinib alone ( Fig. 2D) . In conclusion, 222 our combinatorial approach was sufficient to identify anti-angiogenic compounds present in 223 drug pools.
225
Self-deconvoluting library screen. 226 Theoretically every active compound should present in two pools (one row and one column). 227 We additionally applied a cutoff of at least 40% reduction on primary hyaloid vessels number 228 to be considered a hit. Smaller reductions were considered more likely to be false positives due 229 to combinatorial effects. In the pooling screen, we tested 396 pools, representing 1760 230 compounds, for anti-angiogenic efficacy in the hyaloid vessel assay. Analysis of Diverset® 231 plate #30328 depicts a representative screen result (Fig. 3A) . In that plate, less than three larvae 232 survived treatment in four pools (#30328 A, H, 4, 7). When compounds A4, A7, H4 and H7 233 were re-tested individually, none showed efficacy or toxicity ( Fig. 3B) . Notably, three of 18 234 pools (#30328 D, G & 9) showed a significant reduction in HV vessel numbers ( Fig. 3A) . Two 235 pools exceeded our threshold of 40% PHV reduction (#30328G 75% reduction, p<0.05 and 236 #30328-9 88% reduction, p<0.01) ( Fig. 3A) . To determine if a single compound present in 237 pools G and 9 was responsible for the reduction in PHV, the 17 constituent compounds were 238 tested individually. Compound G9 (chemical name: 4-(2,4-dichlorophenoxy)-N,N-diethyl-1-239 butanamine) initially reproduced significant anti-angiogenic activity but upon repeat testing in 240 dose-response assays its activity-toxicity profile was highly variable and was eliminated from 241 further follow up ( Fig. 3C-E) . 242 In contrast to plate #30328, treatment of larvae with pooled compounds of plate #30325 243 resulted in larval death of 50% and severe developmental problems in all remaining wells. 244 Consequently, all 80 compounds of that plate were tested individually ( Fig. 3F) . Two 245 compounds produced significant anti-angiogenic activity (7A, 7D with PHV 2.3+/-0.5, 2.4+/-246 0.5 and p-values 0.01 and 0.015, respectively), 3 resulted in a significant increase in primary 247 hyaloid vessels (4G, 5H, 8B with PHV 3.8+/-0.4, 3.8+/-0.4, 4.2+/-0.8 and all with p-values of 248 0.01) and 2 were toxic (10G, 11B). None of the significant changes was greater than our selected 249 threshold of 40% and therefore not considered a hit.
250
In total, of the 396 pools screened, 63% didn't surmount the selected threshold of at least 251 40% PHV reduction compared to the control (Fig. 3G) and were dismissed. More problematic was the 89 or 22% toxic pools, wherein survival rates were under 50% (Fig. 3G) . Notably, these 253 predominantly originate from 5 plates with 55 toxic pools, and an additional 12 plates with 34 254 toxic pools (Fig. 3G) . To test all of the constituent compounds would require testing 427 255 individual drugs. In practice, we tested 134 individual drugs from toxic pools and 7% of them 256 showed toxicity and none exerted significant anti-angiogenic activity. In total, 24 pools reduced 257 primary HV by greater than 40% (Fig. 3G) . 6 of these had no corresponding hit in an orthogonal 258 pool and were dismissed as false positives. The remaining 18 pools comprised of 147 259 compounds that were selected for individual testing (Fig. 3B, 3G right panel) . In second round 260 screens, 8 drug hits were identified but 7 of them did not exert a dose-dependent anti-angiogenic 261 activity in tertiary screens.
262
Significantly, compound 30238-G5 showed anti-angiogenic activity when re-tested 263 individually in secondary HV assays and also demonstrated a dose-dependent response at 264 concentrations between 1 and 20 µM in tertiary screens ( Fig. 4A-C) . At 10 and 20 µM, G5 265 caused primary HV numbers to reduce by 25 or 50%, respectively, with no observed adverse 266 effect on survival or overall morphology ( Fig. 4C left panel) . When tested in the alternative 267 inter-segmental vessel (ISV) assay, G5 was inactive indicating a specific anti-angiogenic effect 268 in the eye (Fig. 4D) . 269 270 Metrics. 271 Our approach enabled screening of 1760 compounds of the DIVERSet TM library in only 970 272 treatments. A pre-screen concern with pooling was toxicity levels. We expected from our 
276
In practice, the 22% observed toxicity was lower than expected. Another pre-screen concern 277 was the expected higher variation between technical replicates, but the Fligner-Killeen test 278 showed no difference in variation between groups treated with one drug or a drug pool. Based 279 on the screen metrics, the effect of the pooling strategy on sample sizes was calculated for three 280 different libraries (100, 1,000 or 10,000 compounds) and three scenarios with the same, none 281 or even higher toxicity as experienced in our library screen to demonstrate the usefulness of 282 this method for other screens especially with larger libraries ( Table 2) . Notably, this pooling 283 approach significantly reduced the required workload (Table 1) . This screen required 534 284 person hours to be completed. The single most time-consuming step (50% time) was needed 285 for the eye dissection and blood vessel quantification, which took ~15 min per well. The 
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Our aim was to increase the efficiency of unbiased chemical screens in zebrafish. In particular, 313 our objective was to more effectively screen a randomized chemical library to identify hits with 314 anti-angiogenic activity in the eye. Prior experience in randomized chemical library screening 315 estimated that less than 1% of test drugs are true hits (Reynolds et al., 2016) . A "one compound, only 3% of single drug treated resulted in toxicity. This suggests that the toxic effects arise from 334 the drug combinations more than individual drugs, due to additive or synergistic effects causing 335 higher toxicity (Foucquier and Guedj, 2015) . Generally, zebrafish embryos are a good model 336 for predicting toxicity, and testing on whole organisms can prevent more costly drug failure 337 setbacks with off-target effects later in drug development (Raldua and Pina, 2014) . Despite an 338 increased toxicity, resulting in 424 samples requiring re-testing, the sample numbers (immature 339 larvae) required for the pooling approach was reduced by 45% compared to a "one compound, 340 one well" approach ( Table 1) . Therefore, our pooling screen in immature zebrafish larvae 341 replaces the use of animals and significantly reduces the number of immature animal forms 342 tested, in accordance with the 3R principles (Brannen et al., 2016) . For libraries with less 343 bioactive substances or tested at lower concentrations, a theoretical sample size reduction of 344 69% is possible ( Table 2) . Even if twice the number of pools were impossible to analyze due 345 to toxicity and 50% of the samples had to be re-analyzed individually, the overall sample size 346 would reduce by 11%. Testing in drug pools were expected to cause higher variation in results 347 from replicates. However, the statistical analysis showed no significant difference in variation 348 of groups treated with one drug or a drug pool. Still, we concentrated our efforts on compounds 349 with a high threshold of 40% reduction of primary hyaloid vessel numbers to be considered a 350 hit. This design strategy was successful in screening for anti-angiogenic drugs.
352
In conclusion, phenotype-based drug screening in zebrafish remains a powerful approach for 
